Decoy Biosystems is a San Diego, California-based biotechnology company developing a novel and potentially best-in-class multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy. The company is focused on treatments for unresectable or metastatic solid tumors and lymphomas, which the article notes are responsible for approximately 90 percent of all cancer deaths. Decoy intends to use its recent financing to advance its technology for those indications. The company was accepted into the Johnson & Johnson Innovation, JLABS life science incubator. In October 2018 Decoy Biosystems raised $6.0M in seed funding to support its development work.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2018